Navigation Links
Novel Xeloda(R) Dosing Schedule May Offer Well-Tolerated Alternative for Treatment of Advanced Breast Cancer
Date:4/18/2008

r parts of the body, has an especially poor prognosis, with a five-year survival rate of 27 percent. Currently, there are two and a half million breast cancer survivors in the United States. According to the ACS, breast cancer death rates are going down; the decline may be the result of early detection and treatment.

About the Study

Prior to study initiation, the Norton-Simon mathematical model (Norton et al, AACR 2005) -- which explores how the growth characteristics of a cancer affect response to chemotherapy -- was applied to determine that the maximum impact of Xeloda treatment in breast cancer patients occurs after seven days. Based on this finding, the single-center, open-label phase I/II trial was designed to determine the maximum tolerated dose (MTD) of Xeloda administered orally for seven days, followed by a seven-day rest (7-on/7-off), in patients with advanced-stage breast cancer. MTD was defined as the highest dose for which the incidence of dose-limiting toxicity (DLT) is less than 33 percent. DLT was defined as grade 3/4 hematologic toxicity lasting greater than two weeks despite growth factor support, or any grade 3/4 nonhematologic toxicity.

The Phase I study dose escalation scheme was a standard "3+3" design, using flat dosing that begins at 1,500 mg twice daily and increases by 500 mg/dose level until the MTD is reached. All patients in a cohort were observed for 28 days before enrollment to the next level is permitted to monitor for delayed toxicity.

The study showed that the dose dense regimen was well-tolerated in patients with advanced breast cancer, allowing safe delivery of higher daily doses than routinely used in practice. Of the 21 patients recruited for the trial, 18 were treated with Xeloda and reached a maximum tolerated dose of 2,000 mg twice daily. There were no grade 4/5 toxicities and grade 3 toxicities (which included one dose-limiting incident of hand-foot syndrome at 2,000 mg twice daily and two at 2,0
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... -- Research and Markets has announced the ... Industry Report 2014" report to their offering. ... Global and Chinese Aseptic Packaging Industry Report is a ... the global Aseptic Packaging industry with a focus on ... overview of the industry including definitions, classifications, applications and ...
(Date:7/30/2014)... PITTSBURGH , July 30, 2014   ... Markets Groups Inc.: OTC Pink: UPZS), a Delaware ... a distribution agreement with Larasan Pharmaceutical Corporation ("Larasan"), a ... products.  According to the agreement, US-based Larasan will ... gourmet 6" frozen pizza through Larasan,s vast distribution ...
(Date:7/30/2014)... and PARIS , July 30, 2014 ... and Sanofi (EURONEXT: SAN and NYSE: SNY ... trials of alirocumab in people with hypercholesterolemia met their ... baseline in low-density lipoprotein cholesterol (LDL-C) at 24 weeks ... investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type ...
Breaking Medicine Technology:Global and Chinese Aseptic Packaging Industry Report 2014 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8
... study shows 90-day statin drug claims filled through a mail ... supply from a retail pharmacy. The findings of the study ... management, will be presented at the Academy of Managed Care ... Minn. April 27-29. Waste occurs when patients stop ...
... /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: ... diagnostic ("IVD") company, today announced that it will report ... ("4Q FY2010") and the full fiscal year ended March ... June 2, 2011. The Company will also ...
Cached Medicine Technology:For Patients on Statins, Study Finds Filling 90 Day Supply Prescriptions through Mail Service Compared to Retail Pharmacy is Associated with Less Waste 2China Medical Technologies to Announce Results for the Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2011 on June 2, 2011 2
(Date:7/30/2014)... For patients with asthma, just believing an odor is ... at least 24 hours, a new study indicates. ... you think you smell," study author Cristina Jaen, a ... in a Monell news release. "Asthmatics often ... that an odor is harmful, our bodies react as ...
(Date:7/30/2014)... the vast majority of kids with autism have abnormal ... from children who have trouble processing sensory stimuli, researchers ... be overly sensitive to sound, sight and touch. They ... lack of concentration. Complicating matters, some kids with ... trouble tolerating loud noises, like a vacuum. Others can,t ...
(Date:7/30/2014)... were breastfed for three months or more as ... inflammation associated with cardiovascular and metabolic diseases, according ... University in St. Louis. , "This study shows ... children,s health decades later," said Molly W. Metzger, ... a co-author of the study with Thomas W. ...
(Date:7/30/2014)... July 30, 2014 On July 29, ... the Indian Institute of Public Health, Gandhinagar released a ... India, Volume II: The Way Forward .” The report ... on Policies and Practices to Improve Nutrition Security in ... Father of the Green Revolution" and chair of the ...
(Date:7/30/2014)... “Today, we have said ¡Basta! (enough) to ... promoted to our children and our families. The SWEET ... industry to put the health of people first and ... Delgado, President and CEO of the National Alliance for ... Tax (SWEET) Act by Congresswoman Rosa L. DeLauro. , ...
Breaking Medicine News(10 mins):Health News:Even Thinking an Odor is Harmful May Spur Asthma Symptoms 2Health News:Different Areas of Brain Affected in Autism, Sensory Disorders 2Health News:Different Areas of Brain Affected in Autism, Sensory Disorders 3Health News:Birthweight and breastfeeding have implications for children's health decades later 2Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 2Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 3Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 4Health News:National Alliance for Hispanic Health Statement on Introduction of SWEET Act 2
... A study featured in the November issue of the ... simple questionnaire designed to identify patients at high risk of ... cases of cancer of the original 430 patients who qualified ... The study was conducted in primary care physician offices among ...
... ... with a compound that fights chronic liver disease Infections caused by Hepatitis C. Lloyd ... claim is incurable. The Blueberry Extract has a compound derived from blueberry leaves and ... , ...
... ... Targeted immunotherapy has been an attractive new therapeutic area for a ... cells without damaging surrounding normal tissue. New study results demonstrate high ... lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have ...
... ... its camera housings for underwater use, it turned to ZaGO Manufacturing Company for an answer. ... possibility of water leaking into the switch operating the camera. Vision Tech benefited from ... ...
... ... , ... -- Carmel Pharma, maker of the PhaSeal System for the safe handling of hazardous drugs, ... , , , , ,For safety and ease of use, the non-vented Secondary Set offers the ...
... November 2009 issue of the Journal of Thoracic Oncology ... and treatment may be attributed to health care system discrepancies. ... researchers studied the timing of lung cancer diagnosis and treatment ... patient population within two different hospital systems. David E. Gerber, ...
Cached Medicine News:Health News:Lloyd Wright's Alternative Medicine Marketing Only Blueberry Extract with 45% of Hepatitis C Inhibitor Proanthocyanidin 2Health News:Lloyd Wright's Alternative Medicine Marketing Only Blueberry Extract with 45% of Hepatitis C Inhibitor Proanthocyanidin 3Health News:Immunotherapy Demonstrates Long-Term Success in Treating Lymphoma 2Health News:Immunotherapy Demonstrates Long-Term Success in Treating Lymphoma 3Health News:Immunotherapy Demonstrates Long-Term Success in Treating Lymphoma 4Health News:ZaGO Manufacturing Company Seals the Deal -- Underwater 2Health News:Carmel Pharma Introduces PhaSeal Secondary Set (C60) 2
... Medication Delivery., ,Designed for adolescent ... incorporates an additional lumen and injection ... the cuff., ,SHERIDAN offers three ... CO2 monitoring, pressure monitoring or medication ...
... For Laryngotracheal Instillation of Topical Anesthetic, ... populations, this cuffed tube incorporates an ... spray application of topical anesthetic above ... offers three endotracheal tubes designs which ...
... ,Designed for neonatal and pediatric patient ... monitoring lumen within the wall of the ... Luer lock connector bonded to lumen line ... monitoring or syringe irrigation of medication., ...
SPIRAL-FLEX® Oral Precut Reinforced Tubes...
Medicine Products: